MedTrace Logo

A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic Leukemia

NCT00829647 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2019-04-11

No results posted yet for this study

Summary

Dasatinib and lenalidomide are both prescribed for use in patients with different cancers of the blood. This study is experimental because neither drug has been approved by the Food and Drug Administration for the treatment of chronic lymphocytic leukemia. There are few standard treatments when fludarabine is no longer effective in patients with CLL. Some patients have received additional combination therapy with fludarabine, Campath, bone marrow transplants or supportive care. Dasatinib and lenalidomide have been effective in high-risk CLL patients in other pilot mono therapy studies. The combination of dasatinib and lenalidomide has not been studied in humans before and this study is designed to test whether this combination is safe to use.

Conditions

Interventions

DRUG

dasatinib and lenalidomide

dasatinib will be started at 70mg/day po and lenalidomide will be started at 2.5mg/day po

Sponsors & Collaborators

  • Bristol-Myers Squibb

    collaborator INDUSTRY

  • Celgene Corporation

    collaborator INDUSTRY

  • Scripps Health

    lead OTHER

Principal Investigators

  • Darren Sigal, MD · Staff Scripps Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2009-12-31
Completion
2016-03-01

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00829647 on ClinicalTrials.gov